 The primary objective of this study is to estimate the treatment effect on progression-free survival PFS of panitumumab relative to bevacizumab in combination with mFOLFOX6 chemotherapy as first-line therapy in patients with tumors expressing wild-type KRAS, unresectable mCRC. 